Oxford Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Oxford Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-62,166	Closed	-$438K	–	1035
2019 Q4	$438K	Sell	62,166 -110,540	-64%	-$1.1M	0.01%	1293
2019 Q3	$2.07M	Sell	172,706 -43,050	-20%	-$543K	0.05%	517
2019 Q2	$2.61M	Buy	215,756 +73,811	+52%	+$816K	0.06%	520
2019 Q1	$1.78M	Buy	141,945 +1,231	+0.9%	+$10.9K	0.04%	640
2018 Q4	$947K	Sell	140,714 -46,939	-25%	-$372K	0.02%	892
2018 Q3	$1.9M	Buy	187,653 +23,986	+15%	+$206K	0.04%	691
2018 Q2	$1.12M	Sell	163,667 -1,939	-1%	-$14.9K	0.02%	977
2018 Q1	$1.42M	Buy	165,606 +132,304	+397%	+$2.49M	0.03%	761
2017 Q4	$680K	Buy	+33,302	New	+$591K	0.01%	1087

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Oxford Asset Management's PTGX Position: Q1 2020 in Review

Oxford Asset Management sold out of Protagonist Therapeutics (PTGX) in Q1 2020, closing a stake of 62,166 shares — an estimated $438K sold.

Oxford Asset Management first reported a position in PTGX in Q4 2017 and held it in 9 quarters. The position peaked at $2.61M in Q2 2019. 77 funds tracked by Wall St. Rank hold PTGX as of Q1 2020.

Oxford Asset Management reported no remaining Protagonist Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 62,166 Protagonist Therapeutics shares in Q1 2020, an estimated $438K.
Oxford Asset Management first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 9 quarters.
Oxford Asset Management's Protagonist Therapeutics position peaked at $2.61M in Q2 2019.
77 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.